Pharmacological inhibition of CXCR2/ERK, the signaling pathway downstream of CXCL1 and CXCL2, could markedly decrease CSC activity and sensitize HCC cells to SOR. The gene discussed is CXCL1; the disease is hepatocellular carcinoma.